Clinical trials: Allogeneic Stem Cell Transplantation
Leukemia, Acute Myeloid Leukemia
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
The goal of this clinical research study is to learn if giving busulfan and fludarabine before a stem cell transplant can help control the disease better than the standard method in patients with leukemia, lymphoma, multiple…
- Conditions
- Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT01572662
- Testing
- Fludarabine monophosphate, Busulfan, Stem Cell Infusion
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- M.D. Anderson Cancer Center
Allogeneic Stem Cell Transplantation
Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant
The primary objective of this study is to define the safety and efficacy of recombinant human growth hormone (rh-GH, Genotropin) in a patients undergoing allogeneic transplantation.
- Trial name
- NCT00737113
- Testing
- Genotropin (Recombinant Human Growth Hormone)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mitchell Horwitz, MD
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
This clinical trial is studying how well giving fludarabine phosphate and melphalan together with total-body irradiation followed by donor stem cell transplant works in treating patients with hematologic cancer or bone marrow…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00856388
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia (AML)
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
This prospective observational study aims to evaluate the clinical significance of measurable residual disease (MRD) monitoring using digital PCR (dPCR) in patients with acute myeloid leukemia (AML) following allogeneic…
- Trial name
- NCT07500441
- Testing
- Individualized Digital PCR (dPCR) monitoring
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma
- Trial name
- NCT00867529
- Testing
- rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematological Malignancies, Regulatory T Cell Depletion
Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells
The investigators have previously shown the absence of toxicity of Treg-depleted-DLI and the possibility to triggering alloreactivity (GVHD/GVT) in relapsing patients dealing with hematological malignancies who had never shown…
- Conditions
- Hematological Malignancies, Regulatory T Cell Depletion, Relapse
- Trial name
- DLI-Boost (NCT03236129)
- Testing
- T-reg depleted DLI, Standard DLI
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Methods of T Cell Depletion Trial (MoTD)
A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- MoTD (NCT04888741)
- Testing
- Thymoglobulin, Cyclophosphamide, Cyclosporine
- Where
- 17 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- University of Birmingham
Bronchopulmonary Dysplasia
Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants
The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the prevention of bronchopulmonary dysplasia (BPD) in…
- Trial name
- EVENEW (NCT06279741)
- Testing
- Endotracheopulmonary Instillation, Suspension
- Where
- 8 sites in Belgium, Italy
- Volunteers
- 265 people
- Sponsor
- EXO Biologics S.A.
Allogeneic Transplantation (Non T-cell Depleted)
Phase I Clinical Trial to Assess Safety of UV Phototherapy for the Prevention of GVHD Post Allogeneic SCT
The primary goal of thos study is to assess safety of Ultraviolet (UV) Phototherapy for the Prevention of Graft versus Host Disease after allogeneic stem cell transplantation (Phase I - Clinical trial).
- Trial name
- NCT00524953
- Testing
- EUMATRON - EN 600 NT
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Beta-Thalassemia Major, Graft-versus-host Disease (GVHD)
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
The purpose of this study is to evaluate the basiliximab for prevention of graft-versus-host disease in unrelated allo-genetic hematopoietic stem cell transplantation for thalassemia major.
- Trial name
- NCT02342145
- Testing
- Basiliximab,, Tacrolimus, Methotrexate
- Where
- 3 sites in China
- Volunteers
- 205 people
- Sponsor
- Zhongming Zhang
Graft-Versus-Host Disease, GVHD
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
- Conditions
- Graft-Versus-Host Disease, GVHD, Undefined
- Trial name
- NCT05675930
- Testing
- Photobiomodulation Therapy
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ocular Burns
Corneal Epithelial Autograft With Middle Lamellar Keratoplasty for Severe Ocular Burns
The purpose of this pilot study is to explore whether corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is more effective than limbal autograft (LA) with AMLK for ocular surface…
- Trial name
- NCT03421769
- Testing
- EA and AMLK, LA and AMLK
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yingfeng Zheng
HSCT, Nijmegen Breakage Syndrome
Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome
Nijmegen breakage syndrome is one of the DNA repair defect disorders. A characteristic feature of these syndromes is a predisposition to the development of malignant neoplasms.
- Conditions
- HSCT, Nijmegen Breakage Syndrome, Treosulfan Based Conditioning
- Trial name
- NCT07316595
- Testing
- Treosulfan (Treo)
- Volunteers
- 24 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Parkinson Disease
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease
This trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of Parkinson's Disease
- Trial name
- NCT05152394
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Where
- 2 sites in United States, Greece
- Volunteers
- 20 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Cerebral Palsy
Allogeneic Umbilical Cord Blood Therapy in Children With CP
This open-label study aims to analyze cytokines related to clinical outcomes of allogeneic umbilical cord blood therapy for children with cerebral palsy.
- Trial name
- NCT02025972
- Testing
- Allogeneic umbilical cord blood therapy
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- MinYoung Kim, M.D.
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor, Minimal Residual Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03624530
- Testing
- Tyrosine kinase inhibitor (TKIs)
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
HCT With PTCy in Higher-risk MDS
This study is conducted to evaluate the efficacy of post-transplantation cyclophosphamide with myeloablative or reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with…
- Trial name
- NCT06098313
- Testing
- Cyclophosphamide
- Where
- South Korea
- Volunteers
- 113 people
- Sponsor
- Asan Medical Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS)
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Donor lymphocyte infusion (DLI) based on minimal residual disease (MRD) has been widely adopted worldwide to enhance the graft-versus-leukemia effect following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT07319793
- Testing
- Prophylactic DLI, Preemptive DLI
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Schimke Immuno-osseous Dysplasia
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD
A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the treatment of Schimke immuno-osseous dysplasia
- Trial name
- NCT06769191
- Testing
- CD7 CAR-T cells injection, Allo-HSCT, Kidney Transplantation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.